World Hepatitis Alliance Strategic Plan 2015

Similar documents
Commonwealth Secretariat

End of Year Review 2017 Highlights and achievements

DRAFT STRATEGIC APPROACH & ACTION PLAN For consultation at RDI Annual Meeting Edinburgh, Scotland May 25, 2016

Progress in scaling up voluntary medical male circumcision for HIV prevention in East and Southern Africa

Pfizer Support to European and International Patient Organisations based in Belgium & Luxembourg in 2016

International Bureau for Epilepsy MEMBERSHIP GUIDE Benefits and Responsibilities

Who we are. We envision a world where high quality eye health and vision care is accessible to all people.

RARE DISEASE DAY INFORMATION PACK 28 FEBRUARY 2017 PATIENT INVOLVEMENT: RESEARCH JOIN THE INTERNATIONAL CAMPAIGN TO RAISE AWARENESS FOR RARE DISEASES

World Heart Federation African Summit

10.4 Advocacy, Communication and Social Mobilization Working Group: summary strategic plan,

Public Engagement and Public and Patient Involvement. NIHR Newcastle Biomedical Research Centre and Biomedical Research Unit

World Heart Federation African Summit

FP2020 MIDPOINT COMMUNICATIONS TOOLKIT. #FP2020Progress

WORLD HEPATITIS ALLIANCE: THE AMERICAS REGION

African Health Development & Financing Parliamentary Policy & Budget Action Plan

CONCEPT NOTE THIRD INTERNATIONAL CONFERENCE ON WOMEN S SAFETY: BUILDING INCLUSIVE CITIES SUMMARY NEW DELHI, INDIA NOVEMBER 2010

DRAFT STRATEGIC APPROACH & ACTION PLAN For consultation at RDI Annual Meeting Edinburgh, Scotland May 25, 2016

NCD Alliance Common Interest Group Call 17 July 2012

WORLD CANCER LEADERS SUMMIT EXPRESSIONS OF INTEREST

Who we are. We envision a world where high quality eye health and vision care is accessible to all people.

Village. Event Impact Report June, brought to you by. at the

COMMONWEALTH MINISTERS

Eurasian Harm Reduction Association (EHRA) Strategic Framework

Eurasian Harm Reduction Association (EHRA) Strategic Framework

REPRODUCTIVE, MATERNAL, NEWBORN AND CHILD HEALTH (RMNCH) GLOBAL AND REGIONAL INITIATIVES

Mme. Chair, Deputy Secretary-General, Under-Secretary-General, Excellencies, Distinguished delegates, Ladies and gentlemen,

FISCAL YEAR 2020 APPROPRIATIONS REQUESTS (updated ) USAID Global Health Programs (GHP) and State Department

Social determinants of health: outcome of the World Conference on Social Determinants of Health (Rio de Janeiro, Brazil, October 2011)

Excerpts from the July 22nd Draft Outcome Document

POLIO ERADICATION IN THE AFRICAN REGION: PROGRESS REPORT. Information document EXECUTIVE SUMMARY

The basics a. Mission Statement (unchanged) eurordi s.org

Prevention and control of viral hepatitis: the role and impact of patient and advocacy groups in and outside Europe. Lucca, Italy March 2008

ANNEX Page. AFR/RC61/11 4 July 2011 ORIGINAL: ENGLISH REGIONAL COMMITTEE FOR AFRICA

5 th Islamic Conference of Health Ministers. Resolution. Istanbul, Turkey November 2015 (5-7 Safar 1437H)

ADVOCACY IN ACTION TO ACHIEVE GENDER EQUALITY AND THE SUSTAINABLE DEVELOPMENT GOALS IN KENYA

Cancer prevention and control in the context of an integrated approach

ASEAN Declaration of Commitment on HIV and AIDS: Fast-Tracking and Sustaining HIV and AIDS Responses To End the AIDS Epidemic by 2030

STRATEGIC APPROACH & WORKPLAN 2007

Improving Health Outcomes Through NCD Prevention. Webinar February 21, 2018

Affecting Change... Public affairs, campaigning & political. Caroline Collins, PhD Public Affairs Manager The Alzheimer Society of Ireland March 2012

The Life Course Immunisation Initiative

39th Meeting of the UNAIDS Programme Coordinating Board Geneva, Switzerland. 6-8 December 2016

STRENGTHENING HEALTH SYSTEMS: TOWARD UNIVERSAL HEALTH COVERAGE & GLOBAL HEALTH SECURITY

SIXTY-SEVENTH WORLD HEALTH ASSEMBLY A67/13 Provisional agenda item March Hepatitis

The road towards universal access

Economic and Social Council

BEGINNING THE END OF HOMELESSNESS

Self-assessment in Community Planning Partnerships. Project Evaluation Report

Viral Hepatitis B and C in North African Countries

The new WHO global injection safety policy and campaign

JUNE 2011 CHAMPIONS REPORT

Driving Improvement in Healthcare Our Strategy

Aide Memoire. Distr.: GENERAL. E/ECA/CWD/7/inf.2 3 May 2011

Global health sector strategies on HIV, viral hepatitis and sexually transmitted infections ( )

Mid-term Review of the UNGASS Declaration of. Commitment on HIV/AIDS. Ireland 2006

Changing Lives Nationwide

CAPACITY BUILDING TRAINING WORKSHOP ON VIRAL HEPATITIS FOR AFRICAN UNION MEMBER STATES. Cairo, Egypt

THE MULTI-SECTORAL APPROACH TO AIDS CONTROL IN UGANDA EXECUTIVE SUMMARY

Countdown to 2015: tracking progress, fostering accountability

World Hepatitis Alliance Strategic Plan Finding the Missing Millions. The World Hepatitis Alliance s Strategic Plan

REGIONAL ALLIANCE FOR NATIONAL REGULATORY AUTHORITIES FOR VACCINES IN THE WESTERN PACIFIC. second edition

TUBERCULOSIS AND HIV/AIDS: A STRATEGY FOR THE CONTROL OF A DUAL EPIDEMIC IN THE WHO AFRICAN REGION. Report of the Regional Director.

The Prime Minister s Challenge on Dementia & 2013, G8 Dementia Legacy Making it Happen

Shropshire Voluntary and Community Sector Assembly Information Brochure 2017

Advocacy Strategy

Prevention and control of hepatitis B and C in the European Region of WHO

Summary Report EU Health Award 2017

Where do we go from here?

Draft Concept Note. Launching of Sahel Malaria Elimination Initiative

REGIONAL CONFERENCE FOR LATIN AMERICA AND THE CARIBBEAN (LARC) Thirty-first Session. Panama City, April 2010

Page 1 of 8. CFS:2009/2 Rev.2. CFS 2017/44/12/Rev.1.

The 1992 International Conference on Nutrition:

Terms of reference for Malawi Civil Society Organisations Nutrition Alliance (CSONA)

There is no prevention. There is no cure.

Addressing NCDs: Psoriasis and its Co-morbidities

Hep B United National Summit Report July 27-29, 2016 Washington, D.C.

Mental Health Matters

impact Integrated Missions of PACT Together against Cancer

COMMUNICATION ON ENGAGEMENT Reporting on MI s engagement with the private sector

WELSH GOVERNMENT RESPONSE TO RECOMMENDATIONS FROM THE HEALTH & SOCIAL CARE COMMITTEE: INQUIRY INTO NEW PSYCHOACTIVE SUBSTANCES

1. POSITION TITLE : Technical Advisor, TB and HIV. 2. PERIOD OF PERFORMANCE : Two (2) years, with the possibility of

Pfizer Support to European and International Patient Organisations in 2008

Strengthening Health Systems and Blood Services

SECTION 3: WHAT DOES DIABETES UK DO?

The IAEA and Non-Communicable Diseases The Fight Against Non-Communicable Diseases

Monitoring of the achievement of the health-related Millennium Development Goals

Strategic Direction. At The Kids Cancer Project our vision is to find a cure for kids cancer

FACTS FIGURES A FUTURE

Uniting the world against AIDS

FAO of the UN, WHO and OIE with the collaboration of UNSIC and UNICEF. Background Paper

Elimination of Violence against Women in the Pacific Islands

BUILDING POLITICAL COMMITMENT

1.2 Building on the global momentum

Engaging People Strategy

INFORMATION PACK FOR CANDIDATES. Foundation for Women s Health Research and Development (FORWARD)

DECLARATION. Inaugural. Post-2015: Desired Outcomes February 2015 United Nations Headquarters. United Nations

Pandemic Influenza Preparedness and Response

ViiV Healthcare s Position on Continuous Innovation in Prevention, Testing, Treatment & Care of HIV

WORLD HEALTH ORGANIZATION

ASEAN Activities on Increasing Access to ARV and HIV Related Supplies

Transcription:

World Hepatitis Alliance Strategic Plan 2015

Overview Foreword The World Hepatitis Alliance is a notfor-profit international umbrella Non- Governmental Organisation (NGO). Our membership is composed of over 190 organisations who work in the field of viral hepatitis, representing every region of the world. We are patientled and patient-driven, and we are the global voice for the 400 million people worldwide living with viral hepatitis. Despite its prevalence, viral hepatitis remains a low priority. While this remains the case, we are committed to expanding our work in order to respond to the increasing need for action across the world that too frequently is not addressed by governments or leaders in global health. Through partnership, advocacy, monitoring and continued patient support, we aim to get viral hepatitis higher up the global agenda and to see it given the priority it deserves. To address this urgent need for increased action, our 2015 strategic plan centres on three goals. Firstly, to see many more countries with national strategies in order to encourage governments to commit to tackling viral hepatitis. Secondly, to increase influence of the Alliance and its members to ensure that the voices of viral hepatitis patients are at the forefront of national and global health discussions. Finally, we aim to greatly increase the profile of viral hepatitis amongst policy makers and leaders in global health. To achieve them, each goal has between six and eleven actions. Specific key 2 performance indicators for each goal will allow us to monitor and evaluate our efforts. Together, the goals, actions and performance indicators will direct our work and will ensure that we achieve visible results that will lower the death toll from viral hepatitis. In 2015 we will host the first World Hepatitis Summit in partnership with WHO and the Scottish government. The summit will bring together viral hepatitis stakeholders from across the world with the aim to help countries develop and implement national viral hepatitis plans as well as increase the profile of hepatitis and the work of the Alliance and its members. Though ambitious, the goals and actions set out in our Strategic Plan 2015 are achievable. Furthermore, in following this strategy, projects delivered next year will bring us closer to our ultimate goal, the elimination of hepatitis B and hepatitis C. Charles Gore, President of the World Hepatitis Alliance

Strategic Goals Final goal: Eradication of HBV and HCV Overview 1Many more countries with comprehensive hepatitis strategies in place or at least in development 2Increased influence of the Alliance and its members 3Greatly increased profile of viral hepatitis 3

Strategic Goal 1 Many more countries with effective comprehensive national hepatitis strategies in place or at least in development. Strategic Goal 1 Just a handful of countries currently have such strategies. Without government commitment little progress is possible and the clearest sign of that commitment is a comprehensive national hepatitis strategy that covers everything from awareness and prevention through to treatment. Strong patient advocacy will be critical for this goal and patient group involvement with governments will be crucial to the development of good strategies. Currently patient groups are engaged with governments in some form in about 60 countries. Action 1.1 Action 1.2 Action 1.3 We will promote greater involvement of governments in World Hepatitis Day, which is an extremely useful lever to push for more action and ultimately a national strategy. This will include setting up a campaign theme, liaising with the community and governments as well as WHO. 4 We will ensure regional strategies are in place through our work with WHO and their regional offices. This will include advocacy work with countries ahead of relevant Regional Committee meetings. We will continue to work very closely and support WHO s Global Hepatitis Programme, and assist them with running the Global Hepatitis Network which will help Member States develop/ strengthen hepatitis plans by providing them with expert assistance and tools.

Action 1.4 Action 1.5 Action 1.6 We will second a fulltime staff member to WHO EURO to be the hepatitis focal point for the 53 countries of the region. The position will be covered for two years starting January 2015. The fourth official World Hepatitis Day took place on the 28th July 2014 and saw the largest global response to date, with 157 countries and 87 governments taking part. We will continue to investigate seconding a full-time staff member to WHO AFRO to be the hepatitis focal point for the 47 countries of the region and to produce a regional hepatitis strategy. Action 1.7 Following our appointment as the civil society representatives at the Scientific and Technical Advisory Committee on Viral Hepatitis convened by Dr Margaret Chan, we will continue to provide recommendations to direct its actions. We will continue to support patient advocacy groups in their advocacy work and, where necessary, send a task force on an ad hoc basis to a particular country where significantly more progress could be achieved with our support. Action 1.8 We will work to ensure that key elements such as blood and injection safety as well as access to treatment are part of strategies to tackle the disease. Strategic Goal 1 Action 1.9 Action 1.10 Action 1.11 We will host a World Hepatitis Advisory Committee Meeting, bringing together key actors in the field of access to treatment and health financing to find innovative ways to finance hepatitis B and C programmes. We will host the first World Hepatitis Summit in partnership with WHO and the government of Scotland. See page 6 for more details. Following our hosting of the first World Indigenous Peoples Conference on Viral Hepatitis in 2014, we will organise a follow up meeting to continue to discuss innovative solutions to tackle the burden of hepatitis among this group. 5

Strategic Goal 1 Strategic Goal 1 Key Performance Indicators 2015 100 governments participating in World Hepatitis Day 50 countries with national strategies either in place or in development The Alliance and/or patient advocacy groups engaged with government in 60 countries Regional Committees have adopted regional strategies in the last two regions Delivery of World Hepatitis Summit Delivery of the World Hepatitis Advisory Committee Meeting World Hepatitis Summit In response to the overwhelming global burden of viral hepatitis and the need to establish a forum to examine public health approaches to tackle the disease, the World Hepatitis Alliance is co-hosting the first World Hepatitis Summit in partnership with the Scottish government and the World Health Organization. The Summit will take place every two years as a joint project between the Alliance, different national governments and WHO and will bring together Alliance members, programme leads from member states, public health specialists, pharmaceuticals, global funders and the media. In order to upscale the world s response to viral hepatitis, the Summit aims to strengthen the community voice by promoting the exchange of experiences between patient advocates and organisations from all corners of the globe; to increase the number of countries developing practicable hepatitis action plans and to improve the implementation of plans through sharing of best practice; and to raise the global profile of viral hepatitis. The Summit will also serve as a platform to enhance and consolidate the patient voice in viral hepatitis so prior to the start of the summit, the Alliance will also bring together its members for the first physical Annual General meeting and two days of capacity building workshops. Split by WHO regions, the workshops will be more targeted to address the local needs of the groups and will help them improve on their advocacy skills, media capabilities and fundraising capacity. There will also be the opportunity for our members to meet policy-makers from their countries and a session devoted to benefits for policy-makers in working with advocates. 6

Strategic Goal 2 Increased influence of the Alliance and its members In order to stimulate political interest and action from policy makers evidence has shown that patient organisations have a pivotal role to play. Robust data, effective therapies and public health/clinical champions are vital but without the patient perspective (the human face), civil servants, politicians and governments are less likely to respond effectively. We will continue to promote the work of the Alliance and its members in order to increase our influence with governments and other key global health stakeholders. We will also deliver much needed capacity-building work in the six regions we operate in, focusing on upskilling existing members but also on creating new member organisations. WHO Region of the Americas WHO African Region WHO South-East Asia Region WHO European Region Action 2.1 Action 2.2 Action 2.3 We will host the first World Hepatitis Summit in partnership with WHO and the government of Scotland. See page 6 for more details. We will deliver regional workshops in which we will address our members needs such as building an advocacy voice, supporting their fundraising strategies, their dealings with the media, etc. WHO Eastern Mediterranean Region WHO Western Pacific Region We will focus on creating new patient groups in high prevalence areas where no groups exist. Strategic Goal 2 7

Action 2.4 Action 2.5 Action 2.6 We will develop a training program for healthcare professionals to help them create new patient groups with support from the Alliance. We will work to increase our membership by ensuring that all existing hepatitis patient groups become members and by supporting the creation of new groups. We will attend/be visible at high profile conferences (other than viral hepatitis). Strategic Goal 2 Activities took part all over the world for World Hepatitis Day 2014. Clockwise from top left: Ghana; Romania; Malaysia; Democratic Republic of Congo; Egypt; United States; Austria Action 2.7 We will work with medical societies such as EASL, APASL, AASLD and ALEH and have booths at their main liver meetings. Action 2.8 We will use our special consultative status with the United Nations Economic and Social Council (ECOSOC) to provide our expert opinion on matters related to viral hepatitis and to engage with their statements, thus influencing the global health agenda. Action 2.9 We will expand our interaction and partnership with NGOs in related areas such as International AIDS Society, Union for International Cancer Control, Pan American Health Organization, and International Drugs Policy Consortium. 8

Action 2.10 Action 2.11 We will expand our interaction and partnership work with relevant inter-governmental organisations, such as ASEAN, MERCOSUR, APEC and CICA. We will continue to develop and promote tools to support our members work such as our tool to customise and download posters and our tool to create multilingual leaflets. Examples of the World Hepatitis Day posters customised by members with the Alliance poster tool Strategic Goal 2 Key Performance Indicators 2015 Training DVD for clinicians developed Partnership with 3 international non-hepatitis organisations 6 regional workshops delivered Delivery of World Hepatitis Summit Membership 10 new members each year Strategic Goal 2 Liver Meetings Be present at EASL and AASLD The World Hepatitis Alliance booth for AASLD 2014 set up to showcase the work of the Alliance and its members 9

Strategic Goal 3 Greatly increased profile of viral hepatitis Viral hepatitis is a major public health issue. It is the 7th leading cause of death worldwide, killing more people than HIV/AIDS every year. We will continue to advocate for a higher profile and priority for viral hepatitis. Top 10 causes of death worldwide 1. Ischaemic heart disease 2. Cerebrovascular disease 3. Chronic obstructive pulmonary disease 4. Lower respiratory infections 5. Alzheimer's disease 6. Lung cancer 7. Viral hepatitis 8. Road injuries 9. HIV/AIDS 10. Diabetes Source: Global Burden of Disease Study 2013 Strategic Goal 3 10 The World Hepatitis Alliance represents the voice of 400 million viral hepatitis patients by attending World Health Organization meetings and providing expert advice to Ministers of Health from around the world. By attending and contributing to these high level meetings, the Alliance is at the forefront of global advocacy and gains opportunities to raise viral hepatitis higher up the global agenda.

Action 3.1 Action 3.2 Action 3.3 We will continue to work with champion countries to promote hepatitis as a major public health and to propose World Health Assembly Resolutions. We will work with these countries in particular to mobilise resources for hepatitis, including the engagement of global donors such as the Global Fund, the World Bank, the Gates Foundation, USAID, DFID, etc. We will work with IARC (WHO s cancer research arm) and other oncology partners to ensure that tackling viral hepatitis is seen as a key component of cancer and therefore non-communicable disease prevention. Action 3.4 Action 3.5 Action 3.6 We will work to embed hepatitis in all the developing global health trends. We will host the first World Hepatitis Summit in partnership with WHO and the government of Scotland. See page 6 for more details. We will co-ordinate World Hepatitis Day in partnership with WHO. Strategic Goal 3 Key Performance Indicators 2015 Delivery of Global Hepatitis Summit 150 countries participating in World Hepatitis Day 11 Strategic Goal 3

The World Hepatitis Alliance UK and mailing address: 1, Baden Place London SE1 1YW UK Swiss address: 86bis, route de Frontenex Case Postale 6364 1211 Genève 6 Switzerland Telephone: +41 (0) 22 518 06 16 Email: Contact@worldhepatitisalliance.org